Targeted therapy in melanoma

Emri Gabriella
Debreceni Egyetem, Általános Orvostudományi Kar, Bőrgyógyászati Tanszék, Debrecen

The incidence of melanoma is increasing, and although most of the melanomas are diagnosed at low tumour thickness, the number of metastatic cases is also increasing. In systemic treatment of metastatic and/or unresectable melanoma, targeted molecular inhibitor or immunotherapy can be used as fi rst-line option depending on molecular pathological report. Targeted treatment results in rapid decrease of tumour burden in high percentage of cases; however, the loss of effect is also frequent due to acquired drug resistance. Further improvement on prognosis of metastatic disease is expected from proper sequencing and/or combination of targeted and immunotherapy.

Kapcsolódó cikkek